CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation, a biotechnology firm pioneering a breakthrough technology platform for the development of novel vaccines, announced today that it has received $2.1 million in non-dilutive financing through New Jersey’s Technology Business Tax Certificate Transfer (NOL) Program.
Help employers find you! Check out all the jobs and post your resume.
